Trace Analysis of Wine from 6000 BC

The Neolithic (10,000-3,500 BC) was the age of achievement and expansion. This period represented a transition where food-collecting cultures shifted to food-producing ones, which allowed people to establish year round settlements. Many plants were domesticated including the Eurasian grape, which is believed to be the first grape used to ferment wine. There is an ongoing archeological dig in the Republic of Georgia to investigate the earliest winemaking and the emergence of wine culture as part of the Gadachrili Gora Regional Archaeological Project Excavations (G.R.A.P.E.). Sherds of pottery jars excavated from the dig site, along with corresponding soil samples, were analyzed for the presence of four characteristic grape/wine acids (tartaric acid, citric acid, malic acid, and succinic acid) by high performance liquid chromatography-mass spectrometry. All four acids were detected in trace amounts in every sample; however, there was no significant difference in the amount of acids found in the sherd samples versus the soil samples. As a result, we could not verify the presence of wine in these particular archaeological sherds

A biomolecular archaeological approach to ‘Nordic grog’

The combined archaeological, biomolecular, and archaeobotanical evidence from four sites in Denmark (Nandrup, Kostræde, and Juellinge) and Sweden (Havor on the island of Gotland) provide key reference points for reconstructing ‘Nordic grog’ from ca. 1500 BC to the first century AD. In general, Nordic peoples preferred a hybrid beverage or ‘grog,’ in which many ingredients were fermented together, including locally available honey, local fruit (e.g., bog cranberry, and lingonberry) and cereals (wheat, rye, and/or barley), and sometimes grape wine imported from farther south in Europe. Local herbs/spices, such as bog myrtle, yarrow and juniper, and birch tree resin rounded out the concoction and provide the earliest chemical attestations for their use in Nordic fermented beverages. The aggregate ingredients probably served medicinal purposes, as well as contributing special flavors and aromas. They continued to be important ingredients for many kinds of beverages throughout medieval times and up to the present. The importation of grape wine from southern or central Europe as early as ca. 1100 BC, again chemically attested here for the first time, is of considerable cultural significance. It demonstrates the social and ceremonial prestige attached to wine, especially when it was served up as ‘Nordic grog’ in special wine-sets imported from the south. It also points to an active trading network across Europe as early as the Bronze Age in which amber might have been the principle good exchanged for wine. The presence of pine resin in the beverages likely derives from the imported wine, added as a preservative for its long journey northward

Discovery of a Very Young Field L Dwarf, 2MASS J01415823-4633574

While following up L dwarf candidates selected photometrically from the Two Micron All Sky Survey, we uncovered an unusual object designated 2MASS J01415823-4633574. Its optical spectrum exhibits very strong bands of vanadium oxide but abnormally weak absorptions by titanium oxide, potassium, and sodium. Morphologically such spectroscopic characteristics fall intermediate between old, field early-L dwarfs (log(g)~5) and very late M giants (log(g)~0), leading us to favor low gravity as the explanation for the unique spectral signatures of this L dwarf. Such a low gravity can be explained only if this L dwarf is much lower in mass than a typical old field L dwarf of similar temperature and is still contracting to its final radius. These conditions imply a very young age. Further evidence of youth is found in the near-infrared spectrum, including a triangular-shaped H-band continuum reminiscent of young brown dwarf candidates discovered in the Orion Nebula Cluster. Using the above information along with comparisons to brown dwarf atmospheric and interior models, our current best estimate is that this L dwarf has an age of 1-50 Myr and a mass of 6-25 M_Jupiter. The location of 2MASS 0141-4633 on the sky coupled with a distance estimate of ~35 pc and the above age estimate suggests that this object may be a brown dwarf member of either the 30-Myr-old Tucana/Horologium Association or the ~12-Myr-old beta Pic Moving Group.Comment: Accepted for publication in the 10 March 2006 issue (volume 639) of the Astrophysical Journa

Application of Laser Mass Spectrometry to Art and Archaeology

REMPI laser mass spectrometry is a combination of resonance enhanced multiphoton ionization spectroscopy and time of flight mass spectrometry, This technique enables the collection of mass specific optical spectra as well as of optically selected mass spectra. Analytes are jet-cooled by entrainment in a molecular beam, and this low temperature gas phase analysis has the benefit of excellent vibronic resolution. Utilizing this method, mass spectrometric analysis of historically relevant samples can be simplified and improved; Optical selection of targets eliminates the need for chromatography while knowledge of a target's gas phase spectroscopy allows for facile differentiation of molecules that are in the aqueous phase considered spectroscopically indistinguishable. These two factors allow smaller sample sizes than commercial MS instruments, which in turn will require less damage to objects of antiquity. We have explored methods to optimize REMPI laser mass spectrometry as an analytical tool to archaeology using theobromine and caffeine as molecular markers in Mesoamerican pottery, and are expanding this approach to the field of art to examine laccaic acid in shellacs

Beginning of Viniculture in France

Chemical analyses of ancient organic compounds absorbed into the pottery fabrics of imported Etruscan amphoras (ca. 500-475 B.C.) and into a limestone pressing platform (ca. 425-400 B.C.) at the ancient coastal port site of Lattara in southern France provide the earliest biomolecular archaeological evidence for grape wine and viniculture from this country, which is crucial to the later history of wine in Europe and the rest of the world. The data support the hypothesis that export of wine by ship from Etruria in central Italy to southern Mediterranean France fueled an ever-growing market and interest in wine there, which, in turn, as evidenced by the winepress, led to transplantation of the Eurasian grapevine and the beginning of a Celtic industry in France. Herbal and pine resin additives to the Etruscan wine point to the medicinal role of wine in antiquity, as well as a means of preserving it during marine transport

A Response to Léa Drieu et al., 2020, "Is It Possible to Identify Ancient Wine Production Using Biomolecular Approaches?" (STAR: Science & Technology of Archaeological Research, DOI:10.1080/20548923.2020.1738728)

Comparable to Drieu et al.'s viewpoint, we argue that it is possible to identify ancient Eurasian grape wine by current biomolecular methods, but only in conjunction with the relevant archaeological, archaeobotanical, and other natural and social scientific data. Additionally, we advocate an inductive-deductive working hypothesis model, which is appropriate for the 'historical science' of archaeology. We focus on two key deficiencies of Drieu et al.'s argumentation: (1) the assumption that Guasch-Jané et al. (2004) extracted their ancient samples with potassium hydroxide before testing for tartaric acid/tartrate, and (2) the supposition that 5000-year-old yeast DNA would not be preserved in the hot climate of Egypt but rather represents modern contamination

ACTION:a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

BACKGROUND: H3 K27M-mutant diffuse glioma primarily affects children and young adults, is associated with a poor prognosis, and no effective systemic therapy is currently available. ONC201 (dordaviprone) has previously demonstrated efficacy in patients with recurrent disease. This phase 3 trial evaluates ONC201 in patients with newly diagnosed H3 K27M-mutant glioma.METHODS: ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international phase 3 study of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma. Patients who have completed standard frontline radiotherapy are randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on 2 consecutive days. Primary efficacy endpoints are overall survival (OS) and progression-free survival (PFS); PFS is assessed by response assessment in neuro-oncology high-grade glioma criteria (RANO-HGG) by blind independent central review. Secondary objectives include safety, additional efficacy endpoints, clinical benefit, and quality of life. Eligible patients have histologically confirmed H3 K27M-mutant diffuse glioma, a Karnofsky/Lansky performance status ≥70, and completed first-line radiotherapy. Eligibility is not restricted by age; however, patients must be ≥10 kg at time of randomization. Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. ACTION is currently enrolling in multiple international sites.</p

ACTION:a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

BACKGROUND: H3 K27M-mutant diffuse glioma primarily affects children and young adults, is associated with a poor prognosis, and no effective systemic therapy is currently available. ONC201 (dordaviprone) has previously demonstrated efficacy in patients with recurrent disease. This phase 3 trial evaluates ONC201 in patients with newly diagnosed H3 K27M-mutant glioma.METHODS: ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international phase 3 study of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma. Patients who have completed standard frontline radiotherapy are randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on 2 consecutive days. Primary efficacy endpoints are overall survival (OS) and progression-free survival (PFS); PFS is assessed by response assessment in neuro-oncology high-grade glioma criteria (RANO-HGG) by blind independent central review. Secondary objectives include safety, additional efficacy endpoints, clinical benefit, and quality of life. Eligible patients have histologically confirmed H3 K27M-mutant diffuse glioma, a Karnofsky/Lansky performance status ≥70, and completed first-line radiotherapy. Eligibility is not restricted by age; however, patients must be ≥10 kg at time of randomization. Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. ACTION is currently enrolling in multiple international sites.</p

Early Neolithic wine of Georgia in the South Caucasus

Chemical analyses of ancient organic compounds absorbed into the pottery fabrics from sites in Georgia in the South Caucasus region, dating to the early Neolithic period (ca. 6,000-5,000 BC), provide the earliest biomolecular archaeological evidence for grape wine and viniculture from the Near East, at ca. 6,000-5,800 BC. The chemical findings are corroborated by climatic and environmental reconstruction, together with archaeobotanical evidence, including grape pollen, starch, and epidermal remains associated with a jar of similar type and date. The very large-capacity jars, some of the earliest pottery made in the Near East, probably served as combination fermentation, aging, and serving vessels. They are the most numerous pottery type at many sites comprising the so-called "Shulaveri-Shomutepe Culture" of the Neolithic period, which extends into western Azerbaijan and northern Armenia. The discovery of early sixth millennium BC grape wine in this region is crucial to the later history of wine in Europe and the rest of the world

Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina

BACKGROUND: Earlier reports have shown that the outcome of balloon angioplasty or bypass surgery in unstable angina is less favorable than in stable angina. Recent improvements in percutaneous treatment (stent implantation) and bypass surgery (arterial grafts) warrant reevaluation of the relative merits of either technique in treatment of unstable angina. Methods and Results- Seven hundred fifty-five patients with stable angina were randomly assigned to coronary stenting (374) or bypass surgery (381), and 450 patients with unstable angina were randomly assigned to coronary stenting (226) or bypass surgery (224). All patients had multivessel disease considered to be equally treatable by either technique. Freedom from major adverse events, including death, myocardial infarction, and cerebrovascular events, at 1 year was not different in unstable patients (91.2% versus 88.9%) and stable patients (90.4% versus 92.6%) treated, respectively, with coronary stenting or bypass surgery. Freedom from repeat revascularization at 1 year was similar in unstable and stable angina treated with stenting (79.2% versus 78.9%) or bypass surgery (96.3% versus 96%) but was significantly higher in both unstable and stable patients treated with stenting (16.8% versus 16.9%) compared with bypass surgery (3.6% versus 3.5%). Neither the difference in costs between stented or bypassed stable or unstable angina ($2594 versus$3627) nor the cost-effectiveness was significantly different at 1 year. CONCLUSIONS: There was no difference in rates of death, myocardial infarction, and cerebrovascular event at 1 year in patients with unstable angina and multivessel disease treated with either stented angioplasty or bypass surgery compared with patients with stable angina. The rate of repeat revascularization of both unstable and stable angina was significantly higher in patients with stents